Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly

Masaaki Toyama, Norikazu Sakakibara, Midori Takeda, Mika Okamoto, Koichi Watashi, Takaji Wakita, Masaya Sugiyama, Masashi Mizokami, Masanori Ikeda, Masanori Baba

Research output: Contribution to journalArticle

Abstract

Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside/nucleotides analogs. They are potent inhibitors of HBV DNA polymerase, which also functions as reverse transcriptase. Although nucleoside/nucleotide analogs efficiently suppress HBV replication in liver cells, they cannot eradicate HBV DNA from liver cells and cure the disease. Therefore, it is still mandatory to identify and develop effective inhibitors that target a step other than reverse transcription in the viral replication cycle. HBV capsid assembly is a critical step for viral replication and an attractive target for inhibition of HBV replication. We conducted in silico screening of compounds expected to bind to the HBV capsid dimer-dimer interaction site. The selected compounds were further examined for their anti-HBV activity in vitro. Among the test compounds, novel pyrimidotriazine derivatives were found to be selective inhibitors of HBV replication in HepG2.2.15.7 cells. Among the compounds, 2-[(2,3-dichlorophenyl)amino]-4-(4-tert-butylphenyl)-8-methyl-4H,9H-pyrimido[1,2-a][1,3,5]triazin-6-one was the most active against HBV replication. Studies on its mechanism of action revealed that the compound interfered with HBV capsid assembly determined by a cell-free capsid assembly system. Thus, the pyrimidotriazine derivatives are considered to be potential leads for novel HBV capsid assembly inhibitors.

Original languageEnglish
Number of pages1
JournalVirus research
Volume271
DOIs
Publication statusPublished - Oct 2 2019

Fingerprint

Virus Assembly
Capsid
Hepatitis B virus
Virus Replication
Nucleosides
Nucleotides
Liver
RNA-Directed DNA Polymerase
Chronic Hepatitis B
Virus Diseases
DNA-Directed DNA Polymerase
Computer Simulation
Reverse Transcription

Keywords

  • Antiviral
  • Capsid assembly
  • HBV
  • Pyrimidotriazine

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases
  • Cancer Research

Cite this

Toyama, M., Sakakibara, N., Takeda, M., Okamoto, M., Watashi, K., Wakita, T., ... Baba, M. (2019). Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. Virus research, 271. https://doi.org/10.1016/j.virusres.2019.197677

Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. / Toyama, Masaaki; Sakakibara, Norikazu; Takeda, Midori; Okamoto, Mika; Watashi, Koichi; Wakita, Takaji; Sugiyama, Masaya; Mizokami, Masashi; Ikeda, Masanori; Baba, Masanori.

In: Virus research, Vol. 271, 02.10.2019.

Research output: Contribution to journalArticle

Toyama, M, Sakakibara, N, Takeda, M, Okamoto, M, Watashi, K, Wakita, T, Sugiyama, M, Mizokami, M, Ikeda, M & Baba, M 2019, 'Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly', Virus research, vol. 271. https://doi.org/10.1016/j.virusres.2019.197677
Toyama M, Sakakibara N, Takeda M, Okamoto M, Watashi K, Wakita T et al. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. Virus research. 2019 Oct 2;271. https://doi.org/10.1016/j.virusres.2019.197677
Toyama, Masaaki ; Sakakibara, Norikazu ; Takeda, Midori ; Okamoto, Mika ; Watashi, Koichi ; Wakita, Takaji ; Sugiyama, Masaya ; Mizokami, Masashi ; Ikeda, Masanori ; Baba, Masanori. / Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly. In: Virus research. 2019 ; Vol. 271.
@article{f74bad8e88fc487fbe3a9a3c48ac07ec,
title = "Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly",
abstract = "Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside/nucleotides analogs. They are potent inhibitors of HBV DNA polymerase, which also functions as reverse transcriptase. Although nucleoside/nucleotide analogs efficiently suppress HBV replication in liver cells, they cannot eradicate HBV DNA from liver cells and cure the disease. Therefore, it is still mandatory to identify and develop effective inhibitors that target a step other than reverse transcription in the viral replication cycle. HBV capsid assembly is a critical step for viral replication and an attractive target for inhibition of HBV replication. We conducted in silico screening of compounds expected to bind to the HBV capsid dimer-dimer interaction site. The selected compounds were further examined for their anti-HBV activity in vitro. Among the test compounds, novel pyrimidotriazine derivatives were found to be selective inhibitors of HBV replication in HepG2.2.15.7 cells. Among the compounds, 2-[(2,3-dichlorophenyl)amino]-4-(4-tert-butylphenyl)-8-methyl-4H,9H-pyrimido[1,2-a][1,3,5]triazin-6-one was the most active against HBV replication. Studies on its mechanism of action revealed that the compound interfered with HBV capsid assembly determined by a cell-free capsid assembly system. Thus, the pyrimidotriazine derivatives are considered to be potential leads for novel HBV capsid assembly inhibitors.",
keywords = "Antiviral, Capsid assembly, HBV, Pyrimidotriazine",
author = "Masaaki Toyama and Norikazu Sakakibara and Midori Takeda and Mika Okamoto and Koichi Watashi and Takaji Wakita and Masaya Sugiyama and Masashi Mizokami and Masanori Ikeda and Masanori Baba",
year = "2019",
month = "10",
day = "2",
doi = "10.1016/j.virusres.2019.197677",
language = "English",
volume = "271",
journal = "Virus Research",
issn = "0168-1702",
publisher = "Elsevier",

}

TY - JOUR

T1 - Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly

AU - Toyama, Masaaki

AU - Sakakibara, Norikazu

AU - Takeda, Midori

AU - Okamoto, Mika

AU - Watashi, Koichi

AU - Wakita, Takaji

AU - Sugiyama, Masaya

AU - Mizokami, Masashi

AU - Ikeda, Masanori

AU - Baba, Masanori

PY - 2019/10/2

Y1 - 2019/10/2

N2 - Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside/nucleotides analogs. They are potent inhibitors of HBV DNA polymerase, which also functions as reverse transcriptase. Although nucleoside/nucleotide analogs efficiently suppress HBV replication in liver cells, they cannot eradicate HBV DNA from liver cells and cure the disease. Therefore, it is still mandatory to identify and develop effective inhibitors that target a step other than reverse transcription in the viral replication cycle. HBV capsid assembly is a critical step for viral replication and an attractive target for inhibition of HBV replication. We conducted in silico screening of compounds expected to bind to the HBV capsid dimer-dimer interaction site. The selected compounds were further examined for their anti-HBV activity in vitro. Among the test compounds, novel pyrimidotriazine derivatives were found to be selective inhibitors of HBV replication in HepG2.2.15.7 cells. Among the compounds, 2-[(2,3-dichlorophenyl)amino]-4-(4-tert-butylphenyl)-8-methyl-4H,9H-pyrimido[1,2-a][1,3,5]triazin-6-one was the most active against HBV replication. Studies on its mechanism of action revealed that the compound interfered with HBV capsid assembly determined by a cell-free capsid assembly system. Thus, the pyrimidotriazine derivatives are considered to be potential leads for novel HBV capsid assembly inhibitors.

AB - Chronic hepatitis B virus (HBV) infection is currently treated with nucleoside/nucleotides analogs. They are potent inhibitors of HBV DNA polymerase, which also functions as reverse transcriptase. Although nucleoside/nucleotide analogs efficiently suppress HBV replication in liver cells, they cannot eradicate HBV DNA from liver cells and cure the disease. Therefore, it is still mandatory to identify and develop effective inhibitors that target a step other than reverse transcription in the viral replication cycle. HBV capsid assembly is a critical step for viral replication and an attractive target for inhibition of HBV replication. We conducted in silico screening of compounds expected to bind to the HBV capsid dimer-dimer interaction site. The selected compounds were further examined for their anti-HBV activity in vitro. Among the test compounds, novel pyrimidotriazine derivatives were found to be selective inhibitors of HBV replication in HepG2.2.15.7 cells. Among the compounds, 2-[(2,3-dichlorophenyl)amino]-4-(4-tert-butylphenyl)-8-methyl-4H,9H-pyrimido[1,2-a][1,3,5]triazin-6-one was the most active against HBV replication. Studies on its mechanism of action revealed that the compound interfered with HBV capsid assembly determined by a cell-free capsid assembly system. Thus, the pyrimidotriazine derivatives are considered to be potential leads for novel HBV capsid assembly inhibitors.

KW - Antiviral

KW - Capsid assembly

KW - HBV

KW - Pyrimidotriazine

UR - http://www.scopus.com/inward/record.url?scp=85071700360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071700360&partnerID=8YFLogxK

U2 - 10.1016/j.virusres.2019.197677

DO - 10.1016/j.virusres.2019.197677

M3 - Article

C2 - 31376401

AN - SCOPUS:85071700360

VL - 271

JO - Virus Research

JF - Virus Research

SN - 0168-1702

ER -